JP2018538273A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538273A5
JP2018538273A5 JP2018526571A JP2018526571A JP2018538273A5 JP 2018538273 A5 JP2018538273 A5 JP 2018538273A5 JP 2018526571 A JP2018526571 A JP 2018526571A JP 2018526571 A JP2018526571 A JP 2018526571A JP 2018538273 A5 JP2018538273 A5 JP 2018538273A5
Authority
JP
Japan
Prior art keywords
compound
formula
combination
composition
alkoxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063462 external-priority patent/WO2017091644A1/en
Publication of JP2018538273A publication Critical patent/JP2018538273A/ja
Publication of JP2018538273A5 publication Critical patent/JP2018538273A5/ja
Pending legal-status Critical Current

Links

JP2018526571A 2015-11-23 2016-11-23 虚血性脳卒中を処置するための組成物および方法 Pending JP2018538273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
US62/258,882 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (2)

Publication Number Publication Date
JP2018538273A JP2018538273A (ja) 2018-12-27
JP2018538273A5 true JP2018538273A5 (enExample) 2020-01-09

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526571A Pending JP2018538273A (ja) 2015-11-23 2016-11-23 虚血性脳卒中を処置するための組成物および方法

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN116889562A (zh) * 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
CA3084593A1 (en) * 2017-12-04 2019-06-13 The General Hospital Corporation Cromolyn compositions and methods thereof
KR20200143710A (ko) * 2018-04-09 2020-12-24 더 제너럴 하스피탈 코포레이션 근위축 측삭 경화증 및 관련 장애의 치료를 위한 조합 요법
EP3817739A4 (en) 2018-07-02 2022-04-13 The General Hospital Corporation POWDERED FORMULATIONS OF CROMOLYN SODIUM AND ALPHA-LACTOSE
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071531A1 (en) * 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
RU2428987C2 (ru) * 2004-08-30 2011-09-20 Сео Хонг Ю Нейрозащитное действие растворимой урсодезоксихолевой кислоты в моделях фокальной ишемии
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2391618B1 (en) * 2009-01-29 2019-04-03 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3235509A1 (en) * 2009-03-05 2017-10-25 AbbVie Inc. Il-17 binding proteins
KR20110130463A (ko) * 2009-03-11 2011-12-05 플렉시콘, 인코퍼레이티드 Raf 키나제의 억제를 위한 피롤로[2,3-b]피리딘 유도체
JP6499077B2 (ja) * 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
CA2913235C (en) * 2013-05-23 2021-07-13 Aztherapies, Inc. Methods for delivering cromolyn
CA2928028A1 (en) * 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9962363B2 (en) * 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
CN116889562A (zh) * 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞

Similar Documents

Publication Publication Date Title
JP2018538273A5 (enExample)
JP2018534348A5 (enExample)
JP2016512531A5 (enExample)
JP2009530398A5 (enExample)
JP2010077141A5 (enExample)
JP2019524883A5 (enExample)
JP2019510039A5 (enExample)
JP2020097577A5 (enExample)
JP2015508103A5 (enExample)
JP2013032389A5 (enExample)
JP2018518537A5 (enExample)
JP2017514910A5 (enExample)
JP2013509429A5 (enExample)
JP2017513836A5 (enExample)
JP2013542261A5 (enExample)
JP2016522835A5 (enExample)
JP2016511753A5 (enExample)
JP2015514135A5 (enExample)
JP2012532883A5 (enExample)
JP2019519587A5 (enExample)
JP2016510326A5 (enExample)
JP2011527299A5 (enExample)
JP2015509075A5 (enExample)
JP2019516739A5 (enExample)
JP2016537338A5 (enExample)